Jasper Therapeutics, Inc. 2Q 2026: Net loss $(2.8M), EPS $(0.10) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Jasper Therapeutics reported a narrowed Q2 2026 net loss of $2.8M ($0.10 EPS), down 90% YoY, remaining pre-revenue. Key developments include the July 2026 acquisition of Kira, a $132M preferred-stock financing, and an out-license of KP-301/KP-402 to Mirador. The company discontinued non-core programs to focus on immunology biologics, advancing KP-104 toward Phase 2/3 readiness and planning briquilimab BLA for Q1 2027.
Jasper Therapeutics, Inc. reported a narrowed net loss in the second quarter of 2026, posting a net loss attributable to common stockholders of $(2.8M), or $(0.10) per share diluted, versus a $(26.7M) loss, or $(1.74) per share, in the year‑ago quarter. The company remains pre‑revenue with no product sales reported for the period.
Financial Highlights
- Net income: Net loss attributable to common stockholders of $(2.8M) for 2Q 2026, compared with a net loss of $(26.7M) in 2Q 2025 (‑90% YoY reduction in loss).
- Diluted EPS: Net loss per share, basic and diluted, of $(0.10) for 2Q 2026 versus $(1.74) in the year‑ago quarter.
- Revenue: No product revenue reported; company remains pre‑revenue in this filing.
Business Highlights
- Merger & strategic repositioning: Completed the acquisition of Kira in July 2026, consolidating the pipeline and refocusing the company on immunology biologics.
- Pipeline milestones: Advancing KP‑104 toward Phase 2/3 readiness with interim data expected in Q4 2026 and end‑of‑Phase 2 planning in H1 2027; pre‑BLA planning for briquilimab targeted for Q1 2027.
- Portfolio optimization: Discontinued non‑core programs (asthma, SCID, MDS/AML) following a 2025 reorganization to prioritize higher‑value assets and reduce cash burn.
- Capital and operations: Completed $132M preferred‑stock financing in July 2026 to fund clinical programs and announced an out‑license of KP‑301/KP‑402 to Mirador to concentrate resources on priority programs.
Original SEC Filing: Jasper Therapeutics, Inc. [ JSPR ] - 10-Q - Aug. 14, 2026